Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tharimmune Inc. (THAR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: THAR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.79% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.59M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 1.06 | 52 Weeks Range 0.95 - 4.41 | Updated Date 06/30/2025 |
52 Weeks Range 0.95 - 4.41 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -149.7% | Return on Equity (TTM) -400.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6787796 | Price to Sales(TTM) - |
Enterprise Value 6787796 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.32 | Shares Outstanding 4212080 | Shares Floating 2334123 |
Shares Outstanding 4212080 | Shares Floating 2334123 | ||
Percent Insiders 39.8 | Percent Institutions 2.56 |
Analyst Ratings
Rating 1 | Target Price 5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tharimmune Inc.
Company Overview
History and Background
Tharimmune, Inc. (formerly known as Advaxis, Inc.) is a clinical-stage biotechnology company focusing on developing novel therapies for inflammation and immunology. Advaxis focused on cancer treatments. The name change and strategic shift to immunology occurred in 2024, marking a significant change in direction.
Core Business Areas
- Inflammation and Immunology: Develops therapies targeting the innate immune system to treat inflammatory and immunological diseases. Its lead product, TH104, is under development for treating steroid-resistant Graft-versus-Host Disease (srGvHD).
Leadership and Structure
Dr. Alan Fuhrman is the current CEO. The company is structured around research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- TH104: A modified synthetic molecule intended to modulate innate immunity and reduce inflammation. It is currently in clinical development for steroid-resistant Graft-versus-Host Disease (srGvHD). Market share data unavailable as the product is still in development. Competitors in the srGvHD space include Kadmon (acquired by Sanofi), Incyte (Jakafi), and several emerging therapies.
Market Dynamics
Industry Overview
The inflammation and immunology market is substantial and growing, driven by the increasing prevalence of autoimmune diseases, inflammatory conditions, and the need for novel therapies with improved efficacy and safety profiles.
Positioning
Tharimmune is positioned as a developer of novel therapies targeting the innate immune system, differentiating itself through its unique mechanism of action.
Total Addressable Market (TAM)
The TAM for inflammation and immunology therapies is estimated to be in the tens of billions of dollars annually. Tharimmune is targeting specific subsegments such as srGvHD, giving it a smaller but still significant potential market. Actual TAM target is srGvHD which is expected to reach ~$500M by 2030
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting innate immunity
- Potential to address unmet needs in inflammatory and immunological diseases
- Experienced leadership team
- Focus on srGvHD a serious disease
Weaknesses
- Clinical-stage company with no approved products
- Limited financial resources
- High risk of clinical trial failure
- Dependence on TH104
Opportunities
- Successful clinical trials could lead to regulatory approval and commercialization
- Partnerships with larger pharmaceutical companies
- Expansion into other inflammatory and immunological indications
- Fast Track approval by FDA
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Adverse events in clinical trials
Competitors and Market Share
Key Competitors
- SNY
- INCY
- MRTX
- BMY
Competitive Landscape
Tharimmune faces significant competition from larger, established pharmaceutical companies with greater resources and approved products. Its competitive advantage lies in its novel therapeutic approach.
Growth Trajectory and Initiatives
Historical Growth: Formerly Advaxis, the company's historical growth is not relevant to its current focus.
Future Projections: Future growth depends on the success of clinical trials for TH104.
Recent Initiatives: Name change to Tharimmune and strategic pivot to immunology.
Summary
Tharimmune is a high-risk, high-reward clinical-stage company with a novel approach to treating inflammatory and immunological diseases. Its success hinges on the clinical development of TH104. The company faces intense competition and regulatory hurdles. However, successful trials could lead to significant shareholder value. They have minimal product revenue and rely on investor confidence.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment in biotech companies is highly speculative and involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tharimmune Inc.
Exchange NASDAQ | Headquaters Bridgewater, NJ, United States | ||
IPO Launch date 2022-01-12 | CEO & Director Mr. Sireesh Appajosyula Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.tharimmune.com |
Full time employees 2 | Website https://www.tharimmune.com | ||
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic conditions with high unmet need in the United States. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH023 which is phase 1 clinical trial used to treat multiple high value autoimmune indications; and HS1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.